A Phase 2 interventional study of Bendamustine and Obinutuzumab in Chronic Lymphocytic Leukemia, sponsored by Genentech, Inc.. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-11.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 3 under way, 1 of them phase 3. bendamustine · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 7th largest by enrollment, is one of 3 that started in 2015, is one of 22 in phase 2, and was the 38th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:
The First Hospital of Jilin University · Sites in China
Ages 18+
By country, each count listing its studies:
bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 26 · Phase 3 6 · Phase 4 1
First in 2001; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 35 across the 46 interventional studies. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 17th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2015, is one of 13 in phase 2, and was the 37th registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
2 of the studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003464The First Hospital of Jilin UniversityPhase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study | 2027-06-01 |
| NCT02153580City of Hope Medical CenterCellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | 2027-08-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open-label, multicenter study to evaluate the safety and efficacy of BG induction therapy in participants with previously untreated CLL. The anticipated time on study treatment is 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received obinutuzumab + bendamustine (BG) induction therapy in 28-day cycles for 6 cycles.
Drug: Bendamustine · Drug: Obinutuzumab
Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m\^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
Also known as: Treanda, Levact
Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
Also known as: GA101, Gazyva™, RO5072759
Percentage of Participants With Complete Response (CR), as Determined by the Investigator Using International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) Guidelines
The CR rate was defined as CR or CR with incomplete blood count recovery (CRi), assessed by the investigator according to iwCLL NCI-WG criteria. The definition of confirmed CR required all of the following criteria as assessed at least 2 months after completion of therapy: peripheral blood lymphocytes \< 4 times 10\^9 cells/L; absence of significant lymphadenopathy, hepatomegaly, or splenomegaly due to CLL involvement; absence of constitutional symptoms; normal complete blood count (CBC) without need for transfusion or exogenous growth factors, as exhibited by neutrophils \>/= 1.5 times 10\^9 cells/L, platelets \> 100 times 10\^9 cells/L, and hemoglobin \> 11.0 g/dL; normocellular BM aspirate with \< 30% lymphocytes; absence of lymphoid nodules; and BM biopsy without CLL activity. Those fulfilling CR criteria but who have persistent anemia, thrombocytopenia, or neutropenia were considered CRi.
Time frame: 2 to 3 months after the last infusion of study treatment (up to approximately 228 to 258 days)
Percentage of Participants With Objective Response of CR or Partial Response (PR) at the End of Induction Therapy, as Determined by the Investigator Using iwCLL NCI-WG Guidelines
CR is defined in the previous outcome measure. The definition of PR required that the following be documented for minimum 2 months: \>/= 50% decrease in peripheral blood lymphocytes from Baseline; reduction in lymphadenopathy; \>/= 50% reduction in spleen or liver enlargement; and CBC with one of the following without need for transfusion or exogenous growth factors: polymorphonuclear leukocytes \>/= 1.5 times 10\^9 cells/L, platelets \> 100 times 10\^9 cells/L or \>/= 50% improvement from Baseline, or hemoglobin \> 11.0 g/dL or \>/= 50% improvement from Baseline.
Time frame: 2 to 3 months after the last infusion of study treatment (up to approximately 228 to 258 days)
Duration of Response Among Participants With Objective Response of CR or PR, as Determined by the Investigator Using iwCLL NCI-WG Guidelines
Duration of response was defined as the time from the first assessment of CR, CRi, PR, or nodular partial response (nPR) to the first documentation of PD or death, whichever occurred first. CR, CRi, and PR are identified in previous outcome measures. Participants with lymphoid nodules who otherwise met CR criteria were considered nPR. Participants with post-baseline response assessments (excluding progressive disease) but with no end-of-induction treatment response available were censored on Day 1, and those with end-of-induction treatment response available but who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.
Time frame: From the first assessment of CR, CRi, PR, or nPR (at up to approximately 228 to 258 days) until disease progression, relapse, or death from any cause, whichever occurred first (up to 46 months)
Progression-Free Survival (PFS), as Determined by the Investigator Using iwCLL NCI-WG Guidelines
PFS was defined as the time from the start of induction treatment (Day 1) to the first occurrence of disease progression, relapse as determined by the investigator using iwCLL NCI WG guidelines, or death (within 28 days after the last dose of study drug), whichever occurred first. Disease progression: at least one of the following: lymphadenopathy; increase in the liver or spleen size by 50% or more or the appearance of hepatomegaly or splenomegaly; an increase in the number of blood lymphocytes by 50% or more with at least 5000 B lymphocytes per microliter; transformation to a more aggressive histology; occurrence of cytopenia (neutropenia, anemia, or thrombocytopenia) attributable to CLL. Relapse: Having achieved CR or PR, but after a period of 6 or more months, having demonstrated evidence of disease progression. Participants who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.
Time frame: Day 1 until disease progression, relapse, or death from any cause, whichever occurred first (up to 46 months)
Overall Survival (OS)
OS was defined as the time from the start of induction treatment to death from any cause. Participants who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.
Time frame: Day 1 until death from any cause (up to 46 months)
Percentage of Participants Who Achieved Minimal Residual Disease (MRD)-Negative Status in Bone Marrow at Any Time During the Study
MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in bone marrow aspirate. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture.
Time frame: Up to 46 months
Percentage of Participants Who Achieved MRD-Negative Status in Peripheral Blood at Any Time During the Study
MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture.
Time frame: Baseline up to 46 months
Time to MRD-Negative Status in Peripheral Blood
MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity if the value is \<10\^-4 (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture. Time to MRD-negative status is defined as the time between MRD positivity (\>= 10\^-4) or the time of first dose treatment for patients who were missing MRD status assessment at baseline to the first achievement of MRD negativity in the peripheral blood.
Time frame: Baseline up to 46 months
Duration of MRD-Negativity in Peripheral Blood Among Participants Who Achieved MRD-Negative Status
MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture. Duration of MRD-negativity among patients who achieved MRD negativity in the study is defined as the period between the first occurrence of MRD-negative status and a subsequent MRD-positive status.
Time frame: Baseline up to 46 months
Minimum Observed Concentration (Ctrough) of Obinutuzumab After Cycle 2
Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state.
Time frame: Pre-infusion (0 hours) on Day 1 Cycle 3 (1 cycle = 28 days)
Ctrough of Obinutuzumab After Cycle 4
Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state.
Time frame: Pre-infusion (0 hours) on Day 1 Cycle 5 (1 cycle = 28 days)
Change From Baseline in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score
The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive change from Day 1, Cycle 1 (baseline) indicates improvement. EOT=end of treatment.
Time frame: Day 1 Cycles 1 (baseline), 3, 6; end of treatment, 2 months after last dose, every 3 months thereafter for 2 years (up to 46 months) (1 cycle = 28 days)
Change From Baseline in the EORTC Quality of Life Questionnaire-Chronic Lymphocytic Leukemia 16 (QLQ-CLL16) Score
The EORTC Quality of Life Questionnaire-Chronic Lymphocytic Leukemia 16 (QLQ-CLL16) module included assessments of fatigue, treatment side effects, disease symptoms, infection, social activities, and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive change from Day 1, Cycle 1 (baseline) indicates improvement. EOT=end of treatment.
Time frame: Day 1 Cycles 1 (baseline), 3, 6; end of treatment, 2 months after last dose, every 3 months thereafter for 2 years (up to 46 months) (1 cycle = 28 days)
Number of Hospitalizations Due to Adverse Events (AEs)
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.
Time frame: Day 1 up to 46 months
Percentage of Participants With Adverse Events (AEs)
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.
Time frame: Day 1 up to 46 months
| Milestone | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Started | 102 |
| Completed | 81 |
| Not completed | 21 |
| Withdrew: Reason not specified | 1 |
| Withdrew: Physician decision | 5 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Death | 3 |
| Withdrew: Adverse event | 11 |
The CR rate was defined as CR or CR with incomplete blood count recovery (CRi), assessed by the investigator according to iwCLL NCI-WG criteria. The definition of confirmed CR required all of the following criteria as assessed at least 2 months after completion of therapy: peripheral blood lymphocytes \< 4 times 10\^9 cells/L; absence of significant lymphadenopathy, hepatomegaly, or splenomegaly due to CLL involvement; absence of constitutional symptoms; normal complete blood count (CBC) without need for transfusion or exogenous growth factors, as exhibited by neutrophils \>/= 1.5 times 10\^9 cells/L, platelets \> 100 times 10\^9 cells/L, and hemoglobin \> 11.0 g/dL; normocellular BM aspirate with \< 30% lymphocytes; absence of lymphoid nodules; and BM biopsy without CLL activity. Those fulfilling CR criteria but who have persistent anemia, thrombocytopenia, or neutropenia were considered CRi.
| percentage of participants | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Percentage of Participants With Complete Response (CR), as Determined by the Investigator Using International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) Guidelines | 50.0 (39.9 to 60.1) |
CR is defined in the previous outcome measure. The definition of PR required that the following be documented for minimum 2 months: \>/= 50% decrease in peripheral blood lymphocytes from Baseline; reduction in lymphadenopathy; \>/= 50% reduction in spleen or liver enlargement; and CBC with one of the following without need for transfusion or exogenous growth factors: polymorphonuclear leukocytes \>/= 1.5 times 10\^9 cells/L, platelets \> 100 times 10\^9 cells/L or \>/= 50% improvement from Baseline, or hemoglobin \> 11.0 g/dL or \>/= 50% improvement from Baseline.
| percentage of participants | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Percentage of Participants With Objective Response of CR or Partial Response (PR) at the End of Induction Therapy, as Determined by the Investigator Using iwCLL NCI-WG Guidelines | 89.2 (81.5 to 94.5) |
Duration of response was defined as the time from the first assessment of CR, CRi, PR, or nodular partial response (nPR) to the first documentation of PD or death, whichever occurred first. CR, CRi, and PR are identified in previous outcome measures. Participants with lymphoid nodules who otherwise met CR criteria were considered nPR. Participants with post-baseline response assessments (excluding progressive disease) but with no end-of-induction treatment response available were censored on Day 1, and those with end-of-induction treatment response available but who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.
| months | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Duration of Response Among Participants With Objective Response of CR or PR, as Determined by the Investigator Using iwCLL NCI-WG Guidelines | NA (NA to NA) |
PFS was defined as the time from the start of induction treatment (Day 1) to the first occurrence of disease progression, relapse as determined by the investigator using iwCLL NCI WG guidelines, or death (within 28 days after the last dose of study drug), whichever occurred first. Disease progression: at least one of the following: lymphadenopathy; increase in the liver or spleen size by 50% or more or the appearance of hepatomegaly or splenomegaly; an increase in the number of blood lymphocytes by 50% or more with at least 5000 B lymphocytes per microliter; transformation to a more aggressive histology; occurrence of cytopenia (neutropenia, anemia, or thrombocytopenia) attributable to CLL. Relapse: Having achieved CR or PR, but after a period of 6 or more months, having demonstrated evidence of disease progression. Participants who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.
| months | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Progression-Free Survival (PFS), as Determined by the Investigator Using iwCLL NCI-WG Guidelines | NA (35.0 to NA) |
OS was defined as the time from the start of induction treatment to death from any cause. Participants who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.
| months | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Overall Survival (OS) | NA (NA to NA) |
MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in bone marrow aspirate. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture.
| percentage of participants | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Percentage of Participants Who Achieved Minimal Residual Disease (MRD)-Negative Status in Bone Marrow at Any Time During the Study | 58.8 (44.2 to 72.4) |
MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture.
| percentage of participants | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Percentage of Participants Who Achieved MRD-Negative Status in Peripheral Blood at Any Time During the Study | 83.2 (74.1 to 90.1) |
MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity if the value is \<10\^-4 (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture. Time to MRD-negative status is defined as the time between MRD positivity (\>= 10\^-4) or the time of first dose treatment for patients who were missing MRD status assessment at baseline to the first achievement of MRD negativity in the peripheral blood.
| months | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Time to MRD-Negative Status in Peripheral Blood | 8.2 (7.1 to 10.3) |
MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture. Duration of MRD-negativity among patients who achieved MRD negativity in the study is defined as the period between the first occurrence of MRD-negative status and a subsequent MRD-positive status.
| months | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Duration of MRD-Negativity in Peripheral Blood Among Participants Who Achieved MRD-Negative Status | 28.9 (23.0 to NA) |
Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state.
| nanograms per milliliter (ng/mL) | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Minimum Observed Concentration (Ctrough) of Obinutuzumab After Cycle 2 | 235.92 ± 48.01 |
Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state.
| nanograms per milliliter (ng/mL) | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Ctrough of Obinutuzumab After Cycle 4 | 264.27 ± 46.45 |
The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive change from Day 1, Cycle 1 (baseline) indicates improvement. EOT=end of treatment.
| score on a scale | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Global Health Status (GHS)/QoL: Cycle 3 | 4.02 ± 21.540 |
| GHS/QoL: Cycle 6 | 5.26 ± 22.478 |
| GHS/QoL: EOT/Early Discontinuation | 5.17 ± 26.731 |
| GHS/QoL: Response Visit | 10.98 ± 21.715 |
| GHS/QoL: 3-Month Follow-Up | 10.25 ± 24.733 |
| GHS/QoL: 6-Month Follow-Up | 5.68 ± 30.140 |
| GHS/QoL: 9-Month Follow-Up | 9.26 ± 23.384 |
| GHS/QoL: 12-Month Follow-Up | 6.43 ± 24.676 |
| GHS/QoL: 15-Month Follow-Up | 6.57 ± 25.969 |
| GHS/QoL: 18-Month Follow-Up | 9.84 ± 26.732 |
| GHS/QoL: 21-Month Follow-Up | 7.60 ± 27.117 |
| GHS/QoL: 24-Month Follow-Up | 8.91 ± 27.388 |
| GHS/QoL: 27-Month Follow-Up | 13.26 ± 24.468 |
| GHS/QoL: 30-Month Follow-Up | 1.66 ± 28.501 |
| Physical Function: Cycle 3 | -2.46 ± 14.948 |
| Physical Function: Cycle 6 | 0.00 ± 12.842 |
| Phys. Function: EOT/Early Discontinuation | 2.62 ± 15.188 |
| Physical Function: Response Visit | 3.90 ± 14.705 |
| Physical Function: 3-Month Follow-Up | 4.14 ± 13.769 |
| Physical Function: 6-Month Follow-Up | 1.62 ± 17.308 |
| Physical Function: 9-Month Follow-Up | 4.95 ± 15.208 |
| Physical Function: 12-Month Follow-Up | 3.00 ± 15.221 |
| Physical Function: 15-Month Follow-Up | 2.44 ± 17.647 |
| Physical Function: 18-Month Follow-Up | 1.11 ± 18.589 |
| Physical Function: 21-Month Follow-Up | 1.37 ± 13.509 |
| Physical Function: 24-Month Follow-Up | 3.10 ± 14.467 |
| Physical Function: 27-Month Follow-Up | 4.22 ± 14.057 |
| Physical Function: 30-Month Follow-Up | 5.34 ± 8.691 |
| Role Function: Cycle 3 | 6.01 ± 24.775 |
| Role Function: Cycle 6 | 4.11 ± 27.193 |
| Role Function: EOT/Early Discontinuation | 10.55 ± 27.108 |
| Role Function: Response Visit | 13.14 ± 29.106 |
| Role Function: 3-Month Follow-Up | 14.87 ± 28.210 |
| Role Function: 6-Month Follow-Up | 10.86 ± 29.453 |
| Role Function: 9-Month Follow-Up | 15.51 ± 27.312 |
| Role Function: 12-Month Follow-Up | 10.63 ± 28.591 |
| Role Function: 15-Month Follow-Up | 12.68 ± 30.920 |
| Role Function: 18-Month Follow-Up | 10.88 ± 33.352 |
| Role Function: 21-Month Follow-Up | 10.95 ± 28.656 |
| Role Function: 24-Month Follow-Up | 11.49 ± 30.780 |
| Role Function: 27-Month Follow-Up | 14.97 ± 30.285 |
| Role Function: 30-Month Follow-Up | -13.33 ± 36.132 |
| Emotional Function: Cycle 3 | 7.91 ± 18.092 |
| Emotional Function: Cycle 6 | 6.29 ± 18.304 |
| Emotional Function: EOT/Early Discont. | 9.60 ± 18.302 |
| Emotional Function: Response Visit | 9.12 ± 18.663 |
| Emotional Function: 3-Month Follow-Up | 8.11 ± 18.861 |
| Emotional Function: 6-Month Follow-Up | 6.94 ± 19.424 |
| Emotional Function: 9-Month Follow-Up | 11.00 ± 13.402 |
| Emotional Function: 12-Month Follow-Up | 7.81 ± 18.793 |
| Emotional Function: 15-Month Follow-Up | 6.34 ± 23.883 |
| Emotional Function: 18-Month Follow-Up | 5.75 ± 22.214 |
| Emotional Function: 21-Month Follow-Up | 7.11 ± 19.597 |
| Emotional Function: 24-Month Follow-Up | 9.77 ± 19.380 |
| Emotional Function: 27-Month Follow-Up | 10.15 ± 18.845 |
| Emotional Function: 30-Month Follow-Up | 8.33 ± 15.591 |
| Cognitive Function: Cycle 3 | 2.55 ± 22.640 |
| Cognitive Function: Cycle 6 | -1.75 ± 25.177 |
| Cognitive Function: EOT/Early Discont. | 0.42 ± 17.697 |
| Cognitive Function: Response Visit | 2.74 ± 20.387 |
| Cognitive Function: 3-Month Follow-Up | 2.25 ± 17.946 |
| Cognitive Function: 6-Month Follow-Up | 1.77 ± 23.043 |
| Cognitive Function: 9-Month Follow-Up | 6.02 ± 17.312 |
| Cognitive Function: 12-Month Follow-Up | 1.48 ± 19.646 |
| Cognitive Function: 15-Month Follow-Up | 2.11 ± 20.878 |
| Cognitive Function: 18-Month Follow-Up | 2.55 ± 20.105 |
| Cognitive Function: 21-Month Follow-Up | 3.19 ± 20.815 |
| Cognitive Function: 24-Month Follow-Up | 4.02 ± 18.550 |
| Cognitive Function: 27-Month Follow-Up | 1.70 ± 16.401 |
| Cognitive Function: 30-Month Follow-Up | -3.33 ± 21.726 |
| Social Function: Cycle 3 | -2.35 ± 21.386 |
| Social Function: Cycle 6 | -4.17 ± 23.590 |
| Social Function: EOT/Early Discontinuation | 2.53 ± 23.279 |
| Social Function: Response Visit | 5.69 ± 24.874 |
| Social Function: 3-Month Follow-Up | 5.41 ± 23.587 |
| Social Function: 6-Month Follow-Up | -0.25 ± 26.872 |
| Social Function: 9-Month Follow-Up | 8.10 ± 19.579 |
| Social Function: 12-Month Follow-Up | 2.74 ± 24.667 |
| Social Function: 15-Month Follow-Up | 3.76 ± 25.696 |
| Social Function: 18-Month Follow-Up | 3.70 ± 27.296 |
| Social Function: 21-Month Follow-Up | 2.70 ± 26.952 |
| Social Function: 24-Month Follow-Up | 5.46 ± 21.032 |
| Social Function: 27-Month Follow-Up | 7.48 ± 23.088 |
| Social Function: 30-Month Follow-Up | -10.00 ± 30.277 |
| Fatigue: Cycle 3 | -4.01 ± 25.433 |
| Fatigue: Cycle 6 | -5.48 ± 24.558 |
| Fatigue: EOT/Early Discontinuation | -11.67 ± 24.324 |
| Fatigue: Response Visit | -16.34 ± 25.291 |
| Fatigue: 3-Month Follow-Up | -15.92 ± 24.266 |
| Fatigue: 6-Month Follow-Up | -13.64 ± 24.171 |
| Fatigue: 9-Month Follow-Up | -17.28 ± 23.947 |
| Fatigue: 12-Month Follow-Up | -13.12 ± 24.261 |
| Fatigue: 15-Month Follow-Up | -11.27 ± 25.441 |
| Fatigue: 18-Month Follow-Up | -13.43 ± 24.946 |
| Fatigue: 21-Month Follow-Up | -13.07 ± 22.465 |
| Fatigue: 24-Month Follow-Up | -14.37 ± 21.429 |
| Fatigue: 27-Month Follow-Up | -14.51 ± 23.373 |
| Fatigue: 30-Month Follow-Up | -2.22 ± 16.480 |
| Nausea/Vomiting: Cycle 3 | 2.33 ± 16.990 |
| Nausea/Vomiting: Cycle 6 | 3.68 ± 14.210 |
| Nausea/Vomiting: EOT/Early Discontinuation | 2.32 ± 13.273 |
| Nausea/Vomiting: Response Visit | -0.39 ± 15.209 |
| Nausea/Vomiting: 3-Month Follow-Up | -1.58 ± 9.624 |
| Nausea/Vomiting: 6-Month Follow-Up | -1.26 ± 12.164 |
| Nausea/Vomiting: 9-Month Follow-Up | -0.23 ± 16.428 |
| Nausea/Vomiting: 12-Month Follow-Up | -1.04 ± 13.350 |
| Nausea/Vomiting: 15-Month Follow-Up | 0.70 ± 13.926 |
| Nausea/Vomiting: 18-Month Follow-Up | -0.23 ± 13.267 |
| Nausea/Vomiting: 21-Month Follow-Up | -1.72 ± 13.240 |
| Nausea/Vomiting: 24-Month Follow-Up | -2.01 ± 14.333 |
| Nausea/Vomiting: 27-Month Follow-Up | -1.70 ± 14.925 |
| Nausea/Vomiting: 30-Month Follow-Up | 10.00 ± 14.910 |
| Pain: Cycle 3 | -3.68 ± 17.969 |
| Pain: Cycle 6 | 0.65 ± 26.826 |
| Pain: EOT/Early Discontinuation | -1.90 ± 21.012 |
| Pain: Response Visit | -4.90 ± 20.865 |
| Pain: 3-Month Follow-Up | -1.80 ± 17.570 |
| Pain: 6-Month Follow-Up | -1.52 ± 20.615 |
| Pain: 9-Month Follow-Up | -0.69 ± 20.448 |
| Pain: 12-Month Follow-Up | -0.21 ± 24.947 |
| Pain: 15-Month Follow-Up | 0.94 ± 26.709 |
| Pain: 18-Month Follow-Up | -0.46 ± 25.326 |
| Pain: 21-Month Follow-Up | -0.00 ± 23.035 |
| Pain: 24-Month Follow-Up | -2.59 ± 19.447 |
| Pain: 27-Month Follow-Up | -5.44 ± 26.654 |
| Pain: 30-Month Follow-Up | 6.67 ± 48.015 |
| Dyspnoea: Cycle 3 | 0.39 ± 27.294 |
| Dyspnoea: Cycle 6 | -1.73 ± 25.874 |
| Dyspnoea: EOT/Early Discontinuation | -5.91 ± 31.013 |
| Dyspnoea: Response Visit | -5.88 ± 30.069 |
| Dyspnoea: 3-Month Follow-Up | -9.46 ± 27.872 |
| Dyspnoea: 6-Month Follow-Up | -8.08 ± 27.463 |
| Dyspnoea: 9-Month Follow-Up | -7.87 ± 29.334 |
| Dyspnoea: 12-Month Follow-Up | -5.83 ± 30.824 |
| Dyspnoea: 15-Month Follow-Up | -5.63 ± 29.270 |
| Dyspnoea: 18-Month Follow-Up | -7.87 ± 28.796 |
| Dyspnoea: 21-Month Follow-Up | -8.82 ± 27.289 |
| Dyspnoea: 24-Month Follow-Up | -7.47 ± 28.642 |
| Dyspnoea: 27-Month Follow-Up | -11.56 ± 31.587 |
| Dyspnoea: 30-Month Follow-Up | -20.00 ± 18.256 |
| Insomnia: Cycle 3 | -6.59 ± 27.450 |
| Insomnia: Cycle 6 | -9.09 ± 24.565 |
| Insomnia: EOT/Early Discontinuation | -9.70 ± 25.684 |
| Insomnia: Response Visit | -10.98 ± 28.354 |
| Insomnia: 3-Month Follow-Up | -9.46 ± 25.596 |
| Insomnia: 6-Month Follow-Up | -14.65 ± 29.312 |
| Insomnia: 9-Month Follow-Up | -12.50 ± 29.306 |
| Insomnia: 12-Month Follow-Up | -9.70 ± 31.193 |
| Insomnia: 15-Month Follow-Up | -13.61 ± 30.643 |
| Insomnia: 18-Month Follow-Up | -8.80 ± 30.640 |
| Insomnia: 21-Month Follow-Up | -7.84 ± 29.991 |
| Insomnia: 24-Month Follow-Up | -14.37 ± 28.691 |
| Insomnia: 27-Month Follow-Up | -10.20 ± 36.136 |
| Insomnia: 30-Month Follow-Up | -6.67 ± 49.443 |
| Appetite Loss: Cycle 3 | -2.71 ± 20.589 |
| Appetite Loss: Cycle 6 | 0.00 ± 26.490 |
| Appetite Loss: EOT/Early Discontinuation | -3.80 ± 18.480 |
| Appetite Loss: Response Visit | -7.06 ± 21.878 |
| Appetite Loss: 3-Month Follow-Up | -9.91 ± 18.896 |
| Appetite Loss: 6-Month Follow-Up | -9.60 ± 18.270 |
| Appetite Loss: 9-Month Follow-Up | -10.80 ± 22.378 |
| Appetite Loss: 12-Month Follow-Up | -8.75 ± 20.364 |
| Appetite Loss: 15-Month Follow-Up | -6.57 ± 24.312 |
| Appetite Loss: 18-Month Follow-Up | -7.41 ± 19.557 |
| Appetite Loss: 21-Month Follow-Up | -4.90 ± 23.928 |
| Appetite Loss: 24-Month Follow-Up | -7.47 ± 20.748 |
| Appetite Loss: 27-Month Follow-Up | -8.16 ± 19.872 |
| Appetite Loss: 30-Month Follow-Up | -6.67 ± 14.906 |
| Constipation: Cycle 3 | 3.92 ± 34.661 |
| Constipation: Cycle 6 | -0.00 ± 24.944 |
| Constipation: EOT/Early Discontinuation | -4.27 ± 18.105 |
| Constipation: Response Visit | -4.36 ± 24.147 |
| Constipation: 3-Month Follow-Up | -5.02 ± 18.979 |
| Constipation: 6-Month Follow-Up | -6.06 ± 19.312 |
| Constipation: 9-Month Follow-Up | -5.16 ± 24.975 |
| Constipation: 12-Month Follow-Up | -3.80 ± 25.028 |
| Constipation: 15-Month Follow-Up | -3.76 ± 19.147 |
| Constipation: 18-Month Follow-Up | -0.46 ± 24.059 |
| Constipation: 21-Month Follow-Up | -2.45 ± 22.538 |
| Constipation: 24-Month Follow-Up | -6.32 ± 21.134 |
| Constipation: 27-Month Follow-Up | -6.80 ± 21.494 |
| Constipation: 30-Month Follow-Up | 0.00 ± 0.000 |
| Diarrhoea: Cycle 3 | 1.18 ± 21.483 |
| Diarrhoea: Cycle 6 | 4.82 ± 24.767 |
| Diarrhoea: EOT/Early Discontinuation | 4.64 ± 29.105 |
| Diarrhoea: Response Visit | 2.75 ± 24.780 |
| Diarrhoea: 3-Month Follow-Up | -2.25 ± 20.886 |
| Diarrhoea: 6-Month Follow-Up | -1.01 ± 24.085 |
| Diarrhoea: 9-Month Follow-Up | 3.24 ± 23.174 |
| Diarrhoea: 12-Month Follow-Up | -0.43 ± 21.816 |
| Diarrhoea: 15-Month Follow-Up | 0.00 ± 25.197 |
| Diarrhoea: 18-Month Follow-Up | -2.78 ± 26.090 |
| Diarrhoea: 21-Month Follow-Up | 3.43 ± 28.875 |
| Diarrhoea: 24-Month Follow-Up | -0.57 ± 22.067 |
| Diarrhoea: 27-Month Follow-Up | 1.36 ± 21.471 |
| Diarrhoea: 30-Month Follow-Up | 0.00 ± 23.568 |
| Financial Difficulty: Cycle 3 | 0.78 ± 25.186 |
| Financial Difficulty: Cycle 6 | -2.19 ± 27.934 |
| Financial Difficulty: EOT/Early Discont. | -1.27 ± 26.923 |
| Financial Difficulty: Response Visit | -3.53 ± 29.107 |
| Financial Difficulty: 3-Month Follow-Up | -5.86 ± 27.784 |
| Financial Difficulty: 6-Month Follow-Up | -7.18 ± 27.947 |
| Financial Difficulty: 9-Month Follow-Up | -7.04 ± 26.972 |
| Financial Difficulty: 12-Month Follow-Up | -3.80 ± 30.188 |
| Financial Difficulty: 15-Month Follow-Up | -8.45 ± 29.125 |
| Financial Difficulty: 18-Month Follow-Up | -6.02 ± 31.313 |
| Financial Difficulty: 21-Month Follow-Up | -6.86 ± 25.471 |
| Financial Difficulty: 24-Month Follow-Up | -7.47 ± 26.523 |
| Financial Difficulty: 27-Month Follow-Up | -11.56 ± 31.587 |
| Financial Difficulty: 30-Month Follow-Up | -13.33 ± 29.813 |
The EORTC Quality of Life Questionnaire-Chronic Lymphocytic Leukemia 16 (QLQ-CLL16) module included assessments of fatigue, treatment side effects, disease symptoms, infection, social activities, and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive change from Day 1, Cycle 1 (baseline) indicates improvement. EOT=end of treatment.
| score on a scale | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Fatigue: Cycle 3 | -12.02 ± 26.892 |
| Fatigue: Cycle 6 | -10.17 ± 26.373 |
| Fatigue: EOT/Early Discontinuation | -12.87 ± 30.306 |
| Fatigue: Response Visit | -21.23 ± 30.759 |
| Fatigue: 3-Month Follow-Up | -20.04 ± 29.323 |
| Fatigue: 6-Month Follow-Up | -17.44 ± 25.418 |
| Fatigue: 9-Month Follow-Up | -22.77 ± 27.780 |
| Fatigue: 12-Month Follow-Up | -17.32 ± 25.569 |
| Fatigue: 15-Month Follow-Up | -14.52 ± 30.153 |
| Fatigue: 18-Month Follow-Up | -15.49 ± 30.122 |
| Fatigue: 21-Month Follow-Up | -16.42 ± 28.646 |
| Fatigue: 24-Month Follow-Up | -24.70 ± 25.621 |
| Fatigue: 27-Month Follow-Up | -19.56 ± 26.597 |
| Fatigue: 30-Month Follow-Up | -6.67 ± 53.489 |
| Side Effects: Cycle 3 | 1.52 ± 12.019 |
| Side Effects: Cycle 6 | 0.07 ± 16.072 |
| Side Effects: EOT/Early Discontinuation | -0.67 ± 16.357 |
| Side Effects: Response Visit | -2.08 ± 14.520 |
| Side Effects: 3-Month Follow-Up | -3.30 ± 12.904 |
| Side Effects: 6-Month Follow-Up | -2.61 ± 15.182 |
| Side Effects: 9-Month Follow-Up | -3.36 ± 14.548 |
| Side Effects: 12-Month Follow-Up | -2.27 ± 14.841 |
| Side Effects: 15-Month Follow-Up | -3.17 ± 14.355 |
| Side Effects: 18-Month Follow-Up | -4.54 ± 14.813 |
| Side Effects: 21-Month Follow-Up | -1.66 ± 16.277 |
| Side Effects: 24-Month Follow-Up | -3.08 ± 13.699 |
| Side Effects: 27-Month Follow-Up | -2.96 ± 14.434 |
| Side Effects: 30-Month Follow-Up | -11.67 ± 4.566 |
| Disease Symptoms: Cycle 3 | -9.56 ± 18.196 |
| Disease Symptoms: Cycle 6 | -8.30 ± 20.039 |
| Disease Symptoms: EOT/Early Discontinuation | -10.02 ± 20.371 |
| Disease Symptoms: Response Visit | -12.67 ± 18.019 |
| Disease Symptoms: 3-Month Follow-Up | -12.20 ± 18.630 |
| Disease Symptoms: 6-Month Follow-Up | -10.13 ± 16.699 |
| Disease Symptoms: 9-Month Follow-Up | -12.28 ± 18.478 |
| Disease Symptoms: 12-Month Follow-Up | -8.62 ± 18.297 |
| Disease Symptoms: 15-Month Follow-Up | -9.05 ± 19.284 |
| Disease Symptoms: 18-Month Follow-Up | -10.41 ± 20.632 |
| Disease Symptoms: 21-Month Follow-Up | -9.16 ± 21.398 |
| Disease Symptoms: 24-Month Follow-Up | -10.71 ± 17.675 |
| Disease Symptoms: 27-Month Follow-Up | -11.41 ± 19.904 |
| Disease Symptoms: 30-Month Follow-Up | -5.00 ± 20.917 |
| Infection: Cycle 3 | 6.20 ± 18.182 |
| Infection: Cycle 6 | 4.11 ± 16.406 |
| Infection: EOT/Early Discontinuation | 1.65 ± 15.199 |
| Infection: Response Visit | 0.76 ± 17.528 |
| Infection: 3-Month Follow-Up | 2.59 ± 20.779 |
| Infection: 6-Month Follow-Up | 3.46 ± 23.611 |
| Infection: 9-Month Follow-Up | 1.45 ± 17.135 |
| Infection: 12-Month Follow-Up | 4.42 ± 22.269 |
| Infection: 15-Month Follow-Up | 2.86 ± 19.602 |
| Infection: 18-Month Follow-Up | 2.62 ± 22.532 |
| Infection: 21-Month Follow-Up | 2.78 ± 18.502 |
| Infection: 24-Month Follow-Up | 0.89 ± 15.134 |
| Infection: 27-Month Follow-Up | 1.45 ± 14.731 |
| Infection: 30-Month Follow-Up | -5.00 ± 9.502 |
| Social Activities: Cycle 3 | -3.92 ± 28.827 |
| Social Activities: Cycle 6 | -3.95 ± 34.412 |
| Social Activities: EOT/Early Discont. | -6.41 ± 33.141 |
| Social Activities: Response Visit | -9.24 ± 33.054 |
| Social Activities: 3-Month Follow-Up | -11.87 ± 27.983 |
| Social Activities: 6-Month Follow-Up | -4.69 ± 33.527 |
| Social Activities: 9-Month Follow-Up | -13.33 ± 28.033 |
| Social Activities: 12-Month Follow-Up | -7.89 ± 27.145 |
| Social Activities: 15-Month Follow-Up | -6.76 ± 34.099 |
| Social Activities: 18-Month Follow-Up | -5.71 ± 31.583 |
| Social Activities: 21-Month Follow-Up | -4.55 ± 32.495 |
| Social Activities: 24-Month Follow-Up | -11.51 ± 28.845 |
| Social Activities: 27-Month Follow-Up | -9.42 ± 29.534 |
| Social Activities: 30-Month Follow-Up | 0.00 ± 66.668 |
| Future Health Worries: Cycle 3 | -20.08 ± 30.329 |
| Future Health Worries: Cycle 6 | -14.04 ± 29.946 |
| Future Health Worries: EOT/Early Discont. | -18.57 ± 32.794 |
| Future Health Worries: Response Visit | -20.24 ± 28.351 |
| Future Health Worries: 3-Month Follow-Up | -25.11 ± 29.805 |
| Future Health Worries: 6-Month Follow-Up | -17.44 ± 30.680 |
| Future Health Worries: 9-Month Follow-Up | -23.47 ± 27.253 |
| Future Health Worries: 12-Month Follow-Up | -19.23 ± 26.053 |
| Future Health Worries: 15-Month Follow-Up | -17.14 ± 33.929 |
| Future Health Worries: 18-Month Follow-Up | -19.72 ± 34.540 |
| Future Health Worries: 21-Month Follow-Up | -21.21 ± 27.820 |
| Future Health Worries: 24-Month Follow-Up | -21.82 ± 30.911 |
| Future Health Worries: 27-Month Follow-Up | -25.36 ± 31.572 |
| Future Health Worries: 30-Month Follow-Up | -6.67 ± 27.892 |
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.
| hospitalizations | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Number of Hospitalizations Due to Adverse Events (AEs) | 1.43 ± 0.634 |
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.
| percentage of participants | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Percentage of Participants With Adverse Events (AEs) | 100 |
Collected over Day 1 up to 46 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Obinutuzumab + Bendamustine (BG) | 7/102 (6.9%) | 31/102 (30.4%) | 101/102 (99%) |
| Event | Obinutuzumab + Bendamustine (BG) |
|---|---|
| PneumoniaInfections and infestations | 7/102 |
| PyrexiaGeneral disorders | 5/102 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/102 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 4/102 |
| DehydrationMetabolism and nutrition disorders | 3/102 |
| Urinary tract infectionInfections and infestations | 2/102 |
| Infusion related reactionInjury, poisoning and procedural complications | 2/102 |
| HypotensionVascular disorders | 2/102 |
| AnaemiaBlood and lymphatic system disorders | 1/102 |
| Cardiac arrestCardiac disorders | 1/102 |
| Event | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 76/102 |
| NauseaGastrointestinal disorders | 54/102 |
| NeutropeniaBlood and lymphatic system disorders | 36/102 |
| FatigueGeneral disorders | 36/102 |
| PyrexiaGeneral disorders | 35/102 |
| RashSkin and subcutaneous tissue disorders | 28/102 |
| ConstipationGastrointestinal disorders | 27/102 |
| DiarrhoeaGastrointestinal disorders | 24/102 |
| VomitingGastrointestinal disorders | 21/102 |
| ThrombocytopeniaBlood and lymphatic system disorders | 20/102 |
| Age, Continuous(years) | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Mean | 62.5 ± 10.79 |
| Sex: Female, Male(Participants) | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Female | 32 |
| Male | 70 |
| Ethnicity (NIH/OMB)(Participants) | Obinutuzumab + Bendamustine (BG) |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 97 |
| Unknown or Not Reported | 4 |
| Race (NIH/OMB)(Participants) | Obinutuzumab + Bendamustine (BG) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 98 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
Ran from Mar 2015 to primary completion in Nov 2016, 19 months.
Results were first posted in Dec 2017, 1 year 1 month after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 19 months is below that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bendamustine · Obinutuzumab
Leukemia, Lymphocytic, Chronic, B-Cell →